Florida Cancer Specialists Physician Studies Featured at American Society of Clinical Oncology 2022 Gastrointestinal Cancers Symposium
Florida Cancer Specialist & Research Institute is the leading community-based oncology practice in Florida with clinical trial opportunities made available to patients at 36 locations in the state.
Fort Myers, Fla., Jan. 24, 2022 – Studies conducted by physicians at Florida Cancer Specialists & Research Institute, LLC (FCS) were featured in poster presentations at American Society of Clinical Oncology (ASCO) 2022 Gastrointestinal Cancers Symposium held in San Francisco, California January 20 – 22, 2022. FCS is the leading community-based oncology practice in Florida with clinical trial opportunities made available to patients at 36 locations in the state. Over the past four years, the majority of new cancer drugs approved for use in the U.S. were studied in clinical trials with FCS participation, prior to approval.
The ASCO GI 2022 Symposium provides a global multidisciplinary forum for new, innovative research related to GI cancer care, highlighting experts who are converting science into optimal patient care. The abstract “Ezabenlimab (BI 754091), an anti-PD-1 antibody, in combination with BI 836880, a VEGF/Ang2-blocking nanobody, in patients (pts) with advanced colorectal cancer (CRC),” includes observations from FCS physicians, Ivor Percent, MD, Maen Hussein, MD, and Viralkumar Bhanderi, MD, who were co-authors. This Phase II study, evaluating the effectiveness of an anti-PD-1 antibody, combined with other agents, found antitumor activity comparable to third-line therapy for this patient population.
“The ability to be involved in cutting edge treatments in my private practice that are saving lives is an innovative approach that has touched so many, saved and changed lives, and moved medicine forward,” said FCS Hematologist and Medical Oncologist Dr. Ivor Percent. “It has allowed the doctors on the front lines to do what we signed up for – to give the newest and greatest treatments, prolong quality of life, and save lives, if not now, in 5 years.”
“A phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 in patients with locally advanced or metastatic solid tumors,” another presentation at ASCO GI 2022, includes observations from FCS physician, Manish R. Patel, MD. This study evaluates the safety, maximum tolerated dose (MTD), pharmacokinetics (PK) profile and preliminary anti-cancer effect of TST001 in patients with locally advanced or metastatic solid gastric tumors.
To view an online version of the abstracts, visit: abstracts.asco.org
